Within the mrna vaccine and therapeutics segmentation, application categories delineate how mRNA platforms create value. Infectious-disease prophylaxis remains the dominant revenue contributor, leveraging rapid payload-swapping to address SARS-CoV-2, influenza, RSV and emerging pathogens; because dose demand scales with global immunization coverage, this segment sets the baseline for manufacturing capacity and cost-per-dose benchmarks. Oncology therapeutics is the fastest-growing slice, where mRNA cocktails encoding neoantigens or immunomodulators command per-protocol prices that are one to two orders of magnitude higher than prophylactic vaccines; commercial potential is gated by proof-of-concept data in melanoma and non-small-cell lung cancer, translating addressable prevalence into multi-billion-dollar peak sales forecasts. Protein-replacement therapies target ultra-rare enzymatic or secreted-protein deficiencies; patient volumes are low but pricing power is extreme, anchoring the upper bound of the market size model. Finally, allergy & autoimmune tolerization is at pre-clinical stages yet offers long-tail optionality, rounding out the market taxonomy.
